PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

C07D 277/42, A61K 31/425, C07D 417/12, A61K 31/44, C07D 277/56, 417/06, 417/14, A61K 31/47, 31/50

(11) International Publication Number:

WO 99/21845

(43) International Publication Date:

92129 (US).

6 May 1999 (06.05.99)

(21) International Application Number:

PCT/US98/22809

(22) International Filing Date:

27 October 1998 (27.10.98)

(30) Priority Data:

60/063,634

27 October 1997 (27.10.97) US

(74) Agents: EVANS, Linda, S. et al.; Agouron Pharmaceuticals, Inc., 10350 North Torrey Pines Road, La Jolla, CA 92037

Diego, CA 92122 (US). XIAO, Wei [CN/US]; 4043 Carmel

Springs Way, San Diego, CA 92130 (US). YANG, Yi [CN/US]; 8976 Gainsborough Avenue, San Diego, CA

60/063,666

28 October 1997 (28.10.97)

US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US Filed on Not furnished (CIP)
Not furnished

(71) Applicant (for all designated States except US): AGOURON PHARMACEUTICALS, INC. [US/US]: 10350 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHONG, Wesley, K., M. [US/US]; 134 Honeycomb Court, Encinitas, CA 92024 (US). CHU, Shao, Song [CN/US]; 1604 Jerrilynn Place, Encinitas, CA 92024 (US). DUVADIE, Rohit, R. [NP/US]; 10320 Maya Linda Road #A-316, San Diego, CA 92024 (US). LI, Lin [CN/US]; 3950 Mahaila Avenue #J-36, San

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(88) Date of publication of the international search report:
19 August 1999 (19.08.99)

(54) Title: 4-AMINOTHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES

(57) Abstract

This invention is directed to aminothiazole compounds of formula (I) wherein R¹ is a substituted or unsubstituted group selected from: C₁₋₆-alkyl; C₁₋₆-alkenyl; C₁₋₆-alkynyl; C₁₋₆-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C_{1.6}-alkyl)-carbonyl; (C_{1.6}-alkyl)-carbonyl; (C_{1.6}-alkyl)-carbonyl; alkyl)-aryl; (C1.6-alkyl)-cycloalkyl; (C1.6-alkyl)-(C1.6-alkoxyl); aryl-(C1.6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C₁₋₆-alkenyl; C₁₋₆-alkenyl; C₁₋₆-alkenyl; hydroxyl; c₁₋₆-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (1) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	* 0	7	~~	
AM	Armenia	FI	Finland	LS	Lesotho	SI	Slovenia
AT	Austria	FR	France	LT	Lithuania	SK	Slovakia
1				LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand	2.1	Zimozowe
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		_
DE	Germany	LI	Liechtenstein	SD	Sudan		-
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

International Application No PCT/US 98/22809

A. CLASSIFICATION OF SUBJECT MATTER
1PC 6 C07D277/42 A61K31/425 C07D417/12 A61K31/44 C07D277/56 C07D417/06 CO7D417/14 A61K31/47 A61K31/50 According to International Patent Classification (IPC) or to both national classification and IPC Minimum documentation searched (classification system followed by classification symbols) IPC 6 CO7D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Category ° Citation of document, with indication, where appropriate, of the relevant passages Y WO 92 20642 A (RHONE-POULENC RORER 1-14,16, INTERNATIONAL (HOLDINGS) INC.) 17 26 November 1992 see claims 1-4,7 WO 95 15758 A (RHONE-POULENC RORER 1-14,16, Y PHARMACEUTICALS INC.) 15 June 1995 see claims 1-3,6,7 WO 96 39145 A (RHONE-POULENC RORER Y 1-14,16, PHARMACEUTICALS INC.) 12 December 1996 see claims 1,2,15 P.X WO 98 33798 A (WARNER LAMBERT COMPANY) 1-4,14, 6 August 1998 cited in the application see claims 1-3,9,20,21,26-36 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the invention "E" earlier document but published on or after the international *X° document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 1 8. 06.99 10 June 1999 **Authorized offices** Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Hartrampf, G Fax: (+31-70) 340-3016

International Application No PCT/US 98/22869

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	
ategory °		
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
1	GEWALD K. ET AL.: "4-Amino-thiazole" JOURNAL FÜR PRAKTISCHE CHEMIE, vol. 35, no. 4, 1967, pages 97-104, XP002095703 cited in the application see compounds VIa and VIb	1-13,16
1	RAJASEKHARAN K.N. ET AL.: "Studies on the synthesis of 5-acyl-2,4-diaminothiazoles from amidinothioureas" SYNTHESIS, vol. 5, 1986, pages 353-355, XP002095704 see compounds 4a-4g and 4i-4m	1-13,16
1	NESTEROV V.N. ET AL.: "Cyclization of nitriles. XXIV. Reactions of cyanamide derivatives of thiocarbamic acids with cyanothioacetamide. Crystal structure of 2-allylamino-4-amino-5-benzoyl-1,3-thiazole" JOURNAL OF ORGANIC CHEMISTRY, USSR, vol. 24, no. 4; April 1988, pages 762-770, XP002095705 see compounds VI, pages 765 and 769	1-13,16
A	JENARDANAN G.C. ET AL.: "1-(N-Arylthiocarbamoyl)amidino-3,5-dimeth ylpyrazoles - preparation and use in heterocycle synthesis" SYNTHETIC COMMUNICATIONS, vol. 27, no. 19, 1997, pages 3457-3462, XP002095706 see compounds 5a - 5e, page 3458	1-13,16
P,A	BINU R. ET AL.: "Synthesis and cyclization of 1-(N-nitroamidino)thioureas to 2,4-diaminothiazoles" ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 30, no. 1, 1998, pages 93-96, XP002095707 see compounds 4a - 4h, page 94	1-13,16

International application No. PCT/US 98/22809

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: 15 because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
2. X Claims Nos.: 1-14, 16, 17 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of Item 2 of Ilrst sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
X No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-12, 13 (partially), 14

Compounds of formula (I) wherein R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment and pharmaceutical compositions containing them

2. Claims: 13 (partially), 16, 17

Compounds of formula (I) wherein R1 is a certain benzenesulfonamide group and R2 is a substituted or unsubstituted carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure and pharmaceutical compositions containing them

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 1-14,16,17

The claims contain the expression "pharmaceutically active metabolite" which is considered to be a functional feature and renders the scope of the claims ambiguous. Due to such a definition the compounds of formula (I) encompass too broad a range of different chemical groups, not supported by any examples in the descriptive part of the application. Thus claims 1 to 14, 16 and 17 are considered to be insufficiently substantiated by the description, cf. Article 6 PCT. The vast number of theoretically conceivable compounds resulting from claims drafted in such an ambiguous way precludes a comprehensive search. Thus the search should not be considered to cover any pharmaceutically active metabolites of the compounds of formula (I).

A further ambiguity arises since some of the examples, see e.g. compounds A(1) - A(4), A(8), A(12), B, C(1) - C(3), C(6), C(18), C(30), C(31), D(1), D(2), D(4), I(6) - I(17) and I(19) - I(23) are obviously not covered by the present claims. Although explicitly made and tested for inhibitory activity of cyclin-dependent kinases, they do neither contain the mandatory ortho-substitution of radical R2 (see claim 1 to 12, 13 and 14), nor the benzenesulfonamide moiety for radical R1 (see claims 13, 16 and 17) which otherwise could be considered to be the distinguishing feature in comparison to the prior art.

information on patent family members

International Application No
PCT/US 98/22809

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9220642 A	A 26-11-1992	AT 159009 T	15-10-1997
		AU 658646 B	27-04-1995
		AU 1993492 A	30-12-1992
		CA 2102780 A	11-11-1992
		DE 69222637 D	13-11-1997
		DE 69222637 T	26-02-1998
		DK 584222 T	23-02-1998
		EP 0584222 A	02-03-1994
		ES 2108120 T	16-12-1997
		GR 3024955 T	30-01-1998
		JP 6507643 T	01-09-1994
		MX 9202181 A	01-05-1993
<i>y</i>		US 5409930 A	25-04-1995
		US 5480883 A	02-01-1996
		US 5710158 A	20-01-1998
		US 5795889 A	18-08-1998
4		US 5646153 A	08-07-1997
		US 5721237 A	24-02-1998
		US 5714493 A	03-02-1998
WO 9515758 A	15-06-1995	US 5480883 A	02-01-1996
		US 5710158 A	20-01-1998
		AU 1305095 A	27-06-1995
		EP 0871448 A	21-10-1998
		-SG 54172 A	16-11-1998
		US 5795889 A	18-08-1998
		US 5646153 A	08-07-1997
		US 5721237 A	24-02-1998
		US 5714493 A	03-02-1998
WO 9639145 A	12-12-1996	US 5721237 A	24-02-1998
		AU 696456 B	10-09-1998
		AU 6104496 A	24-12-1996
		CA 2223016 A	12-12-1996
		CZ 9703503 A	18-03-1998
		EP 0831831 A	01-04-1998
		SI 9620092 A	31-08-1998
		SK 166397 A	03-06-1998
WO 9833798 A	06-08-1998	AU 6648098 A	25-08-1998